Joerg Yogarajah

Dr. Joerg Yogarajah

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JYJoerg Yogarajah
Joerg Yogarajah
JHJulie Hutter
Julie Hutter
PKPatrick Kahle
Patrick Kahle
PBPhilipp Beaujean
Philipp Beaujean
MTMarko Tomic
Marko Tomic
TNThomas Neumann
Thomas Neumann
Background and Aims: Various pulsed field ablation (PFA) systems are currently being developed. Recently, a novel CE-approved circular array PFA catheter (PulseSelect™ PFA System, Medtronic, Minneapolis, MN, USA) was introduced. Data on this commercially available system are sparse. The aim was to elucidate real-world data assessing the feasibility, safety, and acute efficacy of pulmonary vein isolation (PVI) and ablation beyond PVI with this novel ablation system. Methods: Consecutive patients with paroxysmal and persistent atrial fibrillation (AF) undergoing first-time ablation with the circular PFA catheter were enrolled in this study. In patients with persistent AF and left atrial (LA) enlargement (LA area > 20 cm2), additional left atrial roof ablation (LARA) was performed. Those with concomitant typical atrial flutter received adjunctive cavo-tricuspid isthmus (CTI) ablation. Results: A total of 100 AF patients were included (29% female, 50% persistent AF). Of these, 33 patients (33%) underwent adjunctive LARA, 1 patient (1%) received posterior wall isolation, and 6 patients (6%) required additional CTI ablation. The skin-to-skin procedural time averaged 66.3 ± 13.8 min, while the fluoroscopy time and dose area product were 13.7 ± 4.7 min and 6.8 ± 4.9 Gycm2, respectively. Acute PVI was achieved in 100% of pulmonary veins. A bidirectional conduction block of the LARA and CTI lines was confirmed in all patients, and no major adverse events were reported. Conclusions: These real-world data demonstrate the feasibility, safety, and acute efficacy of PVI and ablation beyond PVI using a novel circular array PFA catheter in patients with atrial fibrillation and flutter. The system can easily be integrated with standard PVI workflows. Further and larger studies are warranted to assess the clinical long-term effectiveness and safety of this PFA system.

22 August 2025 in Heart Rhythm O2
Verified
Journal Article
Open access
JYJoerg Yogarajah
Joerg Yogarajah
JHJulie Hutter
Julie Hutter
PKPatrick Kahle
Patrick Kahle
MTMarko Tomic
Marko Tomic
MLMirlinda Lüsebrink
Mirlinda Lüsebrink
TNThomas Neumann
Thomas Neumann
Pulsed field ablation (PFA) is an emerging non-thermal approach for pulmonary vein isolation (PVI) in atrial fibrillation (AF). Comparative real-world data between variable-loop circular catheter (VLCC; VARIPULSE™, Biosense Webster, Inc) and fixed-loop circular catheter (FLCC; PulseSelect™, Medtronic) catheters, including non-PVI ablation, are limited. To compare acute efficacy, procedural characteristics, and safety of PVI, and adjunctive ablations performed with VLCC vs FLCC during clinical implementation. Overall, 90 consecutive patients were studied (first 45 VLCC and 45 FLCC cases). FLCC procedures used fluoroscopic guidance; VLCC was integrated with 3-dimensional mapping, reflecting standard real-world use of each catheter. Additional ablations were performed at the operator’s discretion. Acute outcomes and complications were analyzed. Acute PVI success was 100% in both groups. Additional ablations (cavotricuspid isthmus [CTI], roof lines, posterior wall, superior vena cava [SVC]) were performed in 17 (VLCC) and 15 (FLCC) patients, achieving bidirectional block without Radiofrequency touch-ups. In PVI-only cases, FLCC was associated with shorter median procedure time (67.2 vs 76 min, P < .001), whereas VLCC had reduced fluoroscopy time (8.3 vs 11.4 min, P < .001). Major complication rates were low and comparable (2.2% vs 0%, P = 1). This first clinical comparison demonstrated high acute efficacy and favorable safety profiles, with notable procedural differences reflecting their distinct workflows of 2 circular PFA catheter systems for AF ablation. Likewise, this includes the first reported successful CTI, SVC and mitral isthmus ablation using VLCC reflecting its versatility for ablation. Further research is warranted to assess long-term outcomes and lesion durability.

29 May 2025 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Open access
PDF file
JYJoerg Yogarajah
Joerg Yogarajah
JHJulie Hutter
Julie Hutter
PKPatrick Kahle
Patrick Kahle
PBPhilipp Beaujean
Philipp Beaujean
MTMarko Tomic
Marko Tomic
MKMalte Kuniss
Malte Kuniss
Background: Single-shot ablation systems are widely used for pulmonary vein isolation (PVI) in atrial fibrillation (AF). The use of novel pulsed-field ablation (PFA) systems enables ablation beyond PVI, such as left atrial roof ablation (LARA), which may improve outcomes in persistent AF. Objective: This study aimed to compare the acute efficacy, feasibility, and safety of PVI combined with LARA using three different single-shot ablation systems in patients with persistent AF and left atrial enlargement undergoing their first AF ablation. Methods: Consecutive patients undergoing PVI with LARA using cryoballoon or PFA systems were included. Baseline characteristics, procedural parameters, and complication rates were assessed. Results: We included 125 patients with persistent AF and left atrial dilation, divided into cryoballoon (n = 65), pentaspline PFA (n = 30), and circular PFA (n = 30) groups. Acute PVI was achieved in 100% of veins. Fewer applications were required for LARA with cryoballoon vs. PFA (4 vs. 8 vs. 10, P < 0.001). Conduction block was confirmed in 95%, 100%, and 100% of patients (P = 0.421). Procedural times were longer with cryoballoon (87.0 vs. 64.0 vs. 68.0 min, P < 0.001), but fluoroscopy times were shorter (12.2 vs. 15.3 vs. 15.1 min, P = 0.002). Contrast medium use was higher in the cryoballoon group (P < 0.001). Adverse events were rare and predominantly minor, with three complications in the cryoballoon group and one in the PFA groups (P = 0.493). Conclusion: All single-shot ablation systems demonstrated comparable efficacy and safety for PVI and LARA, with differences in procedural feasibility. Further and larger studies are needed. Graphical

15 May 2026 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
JYJoerg Yogarajah
Joerg Yogarajah
JDJana Dannebaum
Jana Dannebaum
AHAhmed Halim
Ahmed Halim
JSJamschid Sedighi
Jamschid Sedighi
MMMatthias Mensch
Matthias Mensch
AHAndreas Hain
Andreas Hain
Background: Arrhythmia‐induced cardiomyopathy (AIC) is a potentially reversible cause of heart failure triggered by different sustained arrhythmias, but data on its real‐world prevalence, recognition, and outcomes are limited. Objective: To assess frequency, predictors, and outcomes of AIC in patients with newly diagnosed left ventricular systolic dysfunction (LVSD) and concurrent arrhythmia undergoing early rhythm control with a wearable cardioverter‐defibrillator (WCD). Methods: Among 780 WCD‐treated patients (2017–2023), those with newly diagnosed idiopathic LVSD (LVEF < 35%) and persistent arrhythmia (atrial fibrillation/flutter or > 20% ventricular ectopy) were included. Diagnostic workup comprised echocardiography, coronary angiography, and cardiac MRI. Effective rhythm control was achieved via cardioversion, antiarrhythmic drugs, and/or ablation. Follow‐up was up to 6 months. AIC was defined as LVEF improvement > 15% with restored sinus rhythm or suppressed ventricular ectopy. Results: Of 780 WCD patients, 142 (18.2%) had LVSD with arrhythmia; 74 idiopathic cases were analyzed. At a mean follow‐up of 138 days (4.5 months), 54 patients (73%) maintained sinus rhythm or suppressed ventricular ectopy after rhythm control, of whom 32 (59.3%) fulfilled AIC criteria. LVEF improved from 28% to 43% in AIC; 56.3% of AIC patients fully recovered (> 50%). Non‐AIC patients had larger LV dimensions, lower heart rates, more mitral regurgitation, and a non‐significant trend toward more frequent late gadolinium enhancement ( p = 0.073). No parameter reliably predicted AIC; LVEF < 25% predicted lack of full recovery ( p = 0.040). No appropriate WCD shocks occurred. ICD indication decreased from 100% to 17% post‐therapy in AIC and Non‐AIC patients (3.1% vs . 36.4%, p = 0.001). Conclusions: AIC related to atrial fibrillation, flutter, or frequent ventricular ectopy is more prevalent and reversible than often recognized. Early rhythm control under WCD protection, supported by comprehensive diagnostics, allows identification of reversible LVSD and may help prevent unnecessary ICD implantation.

16 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KWKay Felix Weipert
Kay Felix Weipert
JHJulie Hutter
Julie Hutter
MKMalte Kuniss
Malte Kuniss
PKPatrick Kahle
Patrick Kahle
JYJoerg Yogarajah
Joerg Yogarajah
TNThomas Neumann
Thomas Neumann
Background and Aims: Noninvasive mapping allows the identification of patient-specific atrial rotational activity (RA) that might play a key role in the perpetuation of persistent atrial fibrillation (PsAF). So far, the impact of pulmonary vein isolation by cryoballoon (Cryo-PVI) on RA is unclear. Moreover, the long-term effect of periprocedural termination of AF during the ablation procedure is controversial. Methods: Noninvasive electrocardiographic mapping with a 252-electrode vest was performed in 42 patients with PsAF. After the first analysis, Cryo-PVI was performed. The RA was analyzed again and then targeted by radiofrequency catheter ablation. The primary clinical endpoint was periprocedural termination of AF. The secondary endpoint was freedom from any atrial arrhythmia >30 s during a 12-month follow-up. Results: In 33 patients (79%), right atrial RA was identified leading to biatrial ablation, and nine patients (21%) had left atrial RA only. Twelve patients (28.6%) converted from AF to sinus rhythm (SR) (Group A). Thirteen patients (30.9%) converted to atrial tachycardia (AT) (Group B). In 17 patients (40.5%), AF was not terminated by ablation (Group C). After a mean follow-up time of 13.8 months, 26 patients were free from AF and AT (61.9%). In terms of rhythm, control Group A (75%) and B (83.3%) showed higher success rates than Group C (33.3%) (p < 0.01). Cryo-PVI had no substantial impact on RA. Conclusions: The RA-based ablation approach showed acceptable success rates. Periprocedural termination of AF had a positive predictive impact on the outcome. No difference was observed between conversion to SR or to AT. Cryo-PVI had no impact on RA.

18 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EWElias Waezsada
Elias Waezsada
JHJulie Hutter
Julie Hutter
PKPatrick Kahle
Patrick Kahle
JYJoerg Yogarajah
Joerg Yogarajah
JSJohannes Sperzel
Johannes Sperzel
AHAndreas Hain
Andreas Hain
Heart failure with reduced ejection fraction (LV-EF < 35%) is diagnosed in app. 11,000,000 patients worldwide. For the treatment of these patients, guideline directed medical therapy has proven to reduce mortality and rehospitalization regardless of the disease’s etiology. It is implemented to treat clinical symptoms by improving the left ventricular ejection fraction. Patients with a transient risk of ventricular tachycardia and sudden cardiac death can be protected by a defibrillator vest. The defibrillator vest is capable to detect and terminate ventricular arrhythmias during Guideline Directed Medical Therapy (GDMT). It is based on the recommendations of the European society of cardiology for 3 months. Afterwards, the WCD wear time could be prolonged, or, in case of persistent low ejection fraction (LV-EF ≤ 35%), an implantable cardioverter defibrillator (ICD) should be implanted, as shown in the WEARIT-II-registry. Our goal was to evaluate the effects of GDMT on LV-recovery and reduction of ICD implantations under protection with a defibrillator vest—depending on the uptitration of GDMT. Methods: 339 consecutive patients between August 2017 and September 2020 with newly diagnosed cardiomyopathy and an EF ≤ 35% were analyzed retrospectively by chart review. All patients were protected by a wearable cardioverter defibrillator (WCD). GDMT as recommended by the ESC started at discharge from hospital. The left ventricular ejection fraction (LV-EF) was determined by transthoracic echocardiography at week 4, 8 and at week 12 (in case of prolonged WCD wear time). Uptitration was performed after 4 and 8 weeks during patient visits. We focused on baseline medication as per GDMT and the dosage increase at week 4, 8 and 12. The aim was the uptitration to the maximum dosage tolerated by the patient. We also compared the LV-EF improvement in the group with and without uptitration of medication dosage. Results: The patient age was, on average, 63.2 years (SD ± 11.9 years). A total of 129 pts (38%) had ICM, 196 (58%) had NICM (incl 66 pts (19%) with DCM and 51 pts (15%) with Myocarditis, 79 pts (24%) with unknown origin) and 14 pts (4%) had other entities (e.g., Tachycardiomyopathy). In total, 21 pts (6%) had an LV-EF of less than 16%, 130 pts (38%) between 16–25% and 183 pts (54%) between 26–35%. GDMT started at discharge from the hospital included treatment with beta blocker for 327 pts (96.5%), ACE-inhibitors/Angiotensin/ARNI for 283 pts (83.5%) and Mineralcorticoid receptor antagonists (MRA) for 334 pts (88.4%). Uptitration was performed in all groups at a rate of 82.3%, 91.1% and 81.0% after 4 weeks and 64.7%, 50.3% and 66.3% after 8 weeks, respectively. After 4 weeks, 25 pts (7.4%) and, after 8 weeks, 171 pts (50.4%) had an EF increase of 5% or more (mean 14.2%). After 4 weeks, 81 patients had an LV-EF more than 35%. A total of 169 pts had a wear time of 12 weeks and an improvement of LVEF of more than 35%. Interestingly, in our study we did not find a significant difference in LV-EF improvement between the group with no uptitration and the group with uptitration. Conclusions: Guideline-directed medical therapy under protection with a WCD from ventricular arrhythmia can reduce the need for implantation of an ICD and can lead to an improvement of ejection fraction. Interestingly, the LV-EF improvement depends on the GDMT at discharge. Current guidelines recommend an initiation of all therapy columns of GDMT (sacubitril/valsartan, ACE-inhibitor/AT1-blocker, mineralcorticoidreceptorblocker, beta blocker) at once and further uptitration to the maximal dosage (ESC Guidelines 2021). A further uptitration of all drugs of GDMT should lead to improvement of LV-EF and consequently to a reduction in ICD implantations.